Dr. Giancarlo Rizzoli

analysis - action - achievement

Solothurn, Solothurn, Switzerland

About

Global executive experience Strong analytical and leadership skills Capability to structure complex and divergent contexts Profound Knowledge and Experience from Science to Sales Expert in Medical Devices, Biotech (w/o drugs), Desinfection and Analysis / Diagnostics

Experience

  • Verwaltungsrat / Member of the Board at Borer Chemie AG

  • Member of the Board at daygnostics AG

  • Company Owner at Rizzoli Strategy+Solutions GmbH

  • ad-interim Director Hygiene Divison at Borer Chemie AG

  • Senior Client Partner at anfass Life Technologies AG

    assisting. We support organizations actively with management, administration and financial services. We assist both, start-ups and SMEs in the biotech, diagnostics and medical technology sectors strategically and operationally with many years of personal experience. We offer access to a broad expertise and our reliable network of selected partners. incubating. We invest in carefully selected life science start-ups either in cash or expertise and get actively involved. We take care about investor relations and help assessing the value of investment projects and companies. accelerating. We plan and improve added value. We review strategies and optimize companies and their market performance. We identify strategic partners and support M&A processes.

  • CEO at 4D Lifetec AG

  • Head of Business Development, Sales and Marketing at 4D Lifetec AG

  • Delegated CEO at daygnostics AG

    definition and implementation of strategy; preparation; CEO succession planning; investor relations

  • Co CEO at 4D Lifetec AG

    4D Lifetec is a pioneer company in the field of non-invasive, immuno-oncology blood tests for early cancer detection. The company has developed a proprietary, novel DDS biomarker that has the potential to become a key element in the diagnostic cascade for all major cancers. As an immunological assay, this biomarker has clinically proven high sensitivity for early detection (> 90% at stage I), making it an ideal adjunct to increase the early sensitivity of genomic liquid biopsy. 4D Lifetest™ Lung Dx is the company's flagship product, initially marketed with a focus on lung cancer confirmation in the US as well as the EU. Other applications (4D Lifetest™ Breast Dx, 4D Lifetest™ Prostate Dx, 4D Lifetest™ Colon Dx) are already CE IVD certified and ready to enter additional markets worldwide.